ADG-106

• Description:

  ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB) . ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].

• UNSPSC:

  12352203

• Target:

  TNF Receptor

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  [ADG-106]

• References & Citations:

  [1]Ma Y, et al. Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma. Cell Rep Med. 2024 Feb 20;5 (2) :101414.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2